Tag:
Actavis
Latest Headlines
Latest Headlines
WSJ: Novartis said to eye $16B offer for Actavis
Actavis has suddenly become the belle of the ball. The Wall Street Journal reports that Novartis is now entertaining a $16 billion bid for the generics maker after a $13 billion offer from Valeant and a $15 billion bid from Mylan both fell flat.
Actavis nixed a $15B offer from Mylan to zero in on Warner Chilcott
We thought Actavis had a love triangle going with potential merger partners Warner Chilcott and Valeant Pharmaceuticals, as an analyst dubbed it earlier this week. Now, news emerges that it's more like a love quadrangle, with rejections on two sides.
Actavis, Warner in buyout talks potentially worth $5B-plus
While Valeant Pharmaceuticals was chatting up Actavis about a potential merger-of-equals, Actavis was apparently mulling a bid for Warner Chilcott, the Irish drugmaker that specializes in women's health and dermatology.
Even if Actavis buy fails, Valeant looks ready for bigger deals
Valeant CEO Michael Pearson hasn't made a secret of his ambitions. He wants to be within spitting distance of Big Pharma. So, it probably shouldn't have been a surprise that he and Actavis chief Paul Bisaro were talking about a merger. And now, expectations are wide open.
On verge of $13B merger, Valeant and Actavis stop talking
Valeant Pharmaceuticals was on the verge of its biggest deal yet last week. Until merger talks with generics giant Actavis fell apart, that is.
Actavis to make generic tamper-resistant OxyContin
Purdue Pharma and generic drugmaker Actavis have settled their patent suit over a special formulation of the painkiller OxyContin just 10 days the FDA banned generic versions that do not carry abuse resistant technology.
Bayer to face new Yaz rivals as patent goes up in flames
After taking a $500 million charge against 2012 earnings for Yaz and Yasmin-related litigation, Bayer has lost its patent fight with three generics makers intent on selling their own copycats.
Baxter to put $300M into old Genmab plant
Baxter International has picked up the former Genmab antibody plant near Minneapolis for a small sum and will now invest about $300 million to get it ready for its own use.
Valeant, Actavis team up on two more authorized generics
Valeant Pharmaceuticals and Actavis are getting downright buddy-buddy. Less than a week after partnering up on three skin products, the two companies have wrapped up a patent fight over two others. The settlement sets launch dates for both copycat versions, and gives Valeant a share in the proceeds.
AZ's Pulmicort patent loss could cost $100M-plus
A U.S. court has ruled against AstraZeneca in a long-running patent fight over its asthma drug Pulmicort Respules. That means copycat drugmakers can launch their versions, competing with Teva Pharmaceutical's authorized generic.
